Literature DB >> 32938727

A Complement C3-Specific Nanobody for Modulation of the Alternative Cascade Identifies the C-Terminal Domain of C3b as Functional in C5 Convertase Activity.

Henrik Pedersen1, Rasmus K Jensen1, Jens Magnus B Jensen2, Rachel Fox3, Dennis V Pedersen1, Heidi G Olesen1, Annette G Hansen4, Dorte Christiansen5, Sofia M M Mazarakis1, Neal Lojek3, Pernille Hansen1, Trine A F Gadeberg1, Alessandra Zarantonello1, Nick S Laursen1, Tom Eirik Mollnes5,6,7,8, Matthew B Johnson3,9, Beth Stevens3,9, Steffen Thiel4, Gregers R Andersen10.   

Abstract

The complement system is an intricate cascade of the innate immune system and plays a key role in microbial defense, inflammation, organ development, and tissue regeneration. There is increasing interest in developing complement regulatory and inhibitory agents to treat complement dysfunction. In this study, we describe the nanobody hC3Nb3, which is specific for the C-terminal C345c domain of human and mouse complement component C3/C3b/C3c and potently inhibits C3 cleavage by the alternative pathway. A high-resolution structure of the hC3Nb3-C345c complex explains how the nanobody blocks proconvertase assembly. Surprisingly, although the nanobody does not affect classical pathway-mediated C3 cleavage, hC3Nb3 inhibits classical pathway-driven hemolysis, suggesting that the C-terminal domain of C3b has an important function in classical pathway C5 convertase activity. The hC3Nb3 nanobody binds C3 with low nanomolar affinity in an SDS-resistant complex, and the nanobody is demonstrated to be a powerful reagent for C3 detection in immunohistochemistry and flow cytometry. Overall, the hC3Nb3 nanobody represents a potent inhibitor of both the alternative pathway and the terminal pathway, with possible applications in complement research, diagnostics, and therapeutics.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Year:  2020        PMID: 32938727     DOI: 10.4049/jimmunol.2000752

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

Review 1.  Nanobodies Provide Insight into the Molecular Mechanisms of the Complement Cascade and Offer New Therapeutic Strategies.

Authors:  Alessandra Zarantonello; Henrik Pedersen; Nick S Laursen; Gregers R Andersen
Journal:  Biomolecules       Date:  2021-02-17

2.  Multifaceted Activities of Seven Nanobodies against Complement C4b.

Authors:  Karla I De la O Becerra; Wout Oosterheert; Ramon M van den Bos; Katerina T Xenaki; Joseph H Lorent; Maartje Ruyken; Arie Schouten; Suzan H M Rooijakkers; Paul M P van Bergen En Henegouwen; Piet Gros
Journal:  J Immunol       Date:  2022-04-15       Impact factor: 5.426

3.  Structure-Guided Engineering of a Complement Component C3-Binding Nanobody Improves Specificity and Adds Cofactor Activity.

Authors:  Henrik Pedersen; Rasmus Kjeldsen Jensen; Annette Gudmann Hansen; Steen Vang Petersen; Steffen Thiel; Nick Stub Laursen; Gregers Rom Andersen
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.